Pharmaceutical

Keytruda combination treatment for NSCLC falls short in Phase III

The Phase III KEYLYNK-006 study evaluating a Keytruda/Lynparza combination treatment failed to meet its primary endpoints.

Mar 22, 2024 - 00:00
Keytruda combination treatment for NSCLC falls short in Phase III
The Phase III KEYLYNK-006 study evaluating a Keytruda/Lynparza combination treatment failed to meet its primary endpoints.
Read the original article

Tags:

Previous Article

Nouscom extends Series C round to $82m for cancer vaccine trials

Next Article

Molecular glues are the latest craze in pharma research, but what are they?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Esperion snags US label expansion for cardiovascular disease drugs

Esperion snags US label expansion for cardiovascular di...

Mar 26, 2024

FDA accepts Regeneron’s BLA for linvoseltamab for review

FDA accepts Regeneron’s BLA for linvoseltamab for review

Feb 22, 2024

Opinion: Gain-of-function research is about much more than dangerous pathogens

Opinion: Gain-of-function research is about much more t...

Jul 22, 2023